{"component": "definition", "props": {"groups": [{"samples": [{"hash": "2gqxT5fMzgT", "uri": "/contracts/2gqxT5fMzgT#core-countries", "label": "License Agreement (Autolus Therapeutics LTD)", "score": 29.3531827515, "published": true}, {"hash": "aY3pD9Ia1yH", "uri": "/contracts/aY3pD9Ia1yH#core-countries", "label": "License Agreement (Autolus Therapeutics LTD)", "score": 29.3449691992, "published": true}, {"hash": "ddBGOR5C9Ag", "uri": "https://www.sec.gov/Archives/edgar/data/1730463/000119312521203817/d196189dex991.htm", "label": "Autolus Therapeutics PLC", "score": 16.4934976044, "published": false}], "size": 5, "snippet_links": [{"key": "core-country", "type": "definition", "offset": [27, 39]}], "snippet": "means [***] and [***] and \u201cCore Country\u201d means any one of them;", "hash": "3bccc41282111d1842ee172669534cb5", "id": 1}, {"samples": [{"hash": "fqXJuvErXoi", "uri": "/contracts/fqXJuvErXoi#core-countries", "label": "License Agreement (Genvec Inc)", "score": 18.0, "published": true}, {"hash": "1AgjszRbgsW", "uri": "/contracts/1AgjszRbgsW#core-countries", "label": "License Agreement (Genvec Inc)", "score": 18.0, "published": true}], "size": 5, "snippet_links": [{"key": "the-united-states", "type": "definition", "offset": [6, 23]}, {"key": "united-kingdom", "type": "definition", "offset": [48, 62]}], "snippet": "means the United States, Canada, Mexico, Japan, United Kingdom, France, Germany and Italy.", "hash": "25714d8a5a9eb7b288321b448437e544", "id": 2}, {"samples": [{"hash": "cSZcXSxhxTy", "uri": "/contracts/cSZcXSxhxTy#core-countries", "label": "License Agreement (Omthera Pharmaceuticals, Inc.)", "score": 24.2470910335, "published": true}, {"hash": "9g1MjtmreSG", "uri": "/contracts/9g1MjtmreSG#core-countries", "label": "License Agreement (Omthera Pharmaceuticals, Inc.)", "score": 24.151266256, "published": true}], "size": 4, "snippet_links": [], "snippet": "means [\u2026***\u2026];", "hash": "8808c9b44592405e652dece0a40c7013", "id": 3}, {"samples": [{"hash": "bvVyxjPg1gN", "uri": "/contracts/bvVyxjPg1gN#core-countries", "label": "Ex Us Commercialization Agreement (Foundation Medicine, Inc.)", "score": 29.5420944559, "published": true}, {"hash": "5vExVQEjg3f", "uri": "/contracts/5vExVQEjg3f#core-countries", "label": "Ex Us Commercialization Agreement", "score": 29.340862423, "published": true}, {"hash": "2ZBTl3oFKTT", "uri": "/contracts/2ZBTl3oFKTT#core-countries", "label": "Ex Us Commercialization Agreement (Foundation Medicine, Inc.)", "score": 29.3312799452, "published": true}], "size": 3, "snippet_links": [{"key": "the-term", "type": "definition", "offset": [15, 23]}, {"key": "amendment-to-this-agreement", "type": "clause", "offset": [73, 100]}, {"key": "additional-countries", "type": "definition", "offset": [113, 133]}, {"key": "approved-by-the-joc", "type": "definition", "offset": [134, 153]}], "snippet": "means [\u2026***\u2026]. The term \u201cCore Countries\u201d may be updated, without further amendment to this Agreement, to include additional countries approved by the JOC.", "hash": "b79594ebb6a86f7d8682e359939e4cda", "id": 4}, {"samples": [{"hash": "3IIGQyIz5ZP", "uri": "/contracts/3IIGQyIz5ZP#core-countries", "label": "Licence Agreement (Achilles Therapeutics PLC)", "score": 32.1868583162, "published": true}, {"hash": "hAiyV5GW6KI", "uri": "/contracts/hAiyV5GW6KI#core-countries", "label": "Licence Agreement (Achilles Therapeutics PLC)", "score": 32.1622176591, "published": true}, {"hash": "bgEMbFqVNUk", "uri": "/contracts/bgEMbFqVNUk#core-countries", "label": "Licence Agreement (Achilles Therapeutics LTD)", "score": 32.0882956879, "published": true}], "size": 3, "snippet_links": [{"key": "in-clause", "type": "clause", "offset": [22, 31]}], "snippet": "has the meaning given in Clause 16.8;", "hash": "e16d2f773818bfadbbda2c24499d082f", "id": 5}, {"samples": [{"hash": "dFn5th9ObHg", "uri": "/contracts/dFn5th9ObHg#core-countries", "label": "Collaboration and License Agreement (Pharmacopeia Inc)", "score": 18.0, "published": true}, {"hash": "bqlQkktWpG", "uri": "/contracts/bqlQkktWpG#core-countries", "label": "Collaboration and License Agreement (Pharmacopeia Inc)", "score": 18.0, "published": true}], "size": 3, "snippet_links": [{"key": "the-united-states", "type": "definition", "offset": [6, 23]}, {"key": "european-patent-convention", "type": "definition", "offset": [71, 97]}, {"key": "european-patent-office", "type": "definition", "offset": [102, 124]}], "snippet": "means the United States, Canada, Europe (members -------------- of the European Patent Convention via European Patent Office Applications) and Japan.", "hash": "a6991f5b37d2274f4b5f246282ba33c1", "id": 6}, {"samples": [{"hash": "5tYt6j7DDgf", "uri": "/contracts/5tYt6j7DDgf#core-countries", "label": "Development and Commercialization Agreement (Bioverativ Inc.)", "score": 27.9678302533, "published": true}, {"hash": "9KhIg4i67dP", "uri": "/contracts/9KhIg4i67dP#core-countries", "label": "Development and Commercialization Agreement (Bioverativ Inc.)", "score": 27.803559206, "published": true}], "size": 2, "snippet_links": [{"key": "on-schedule", "type": "definition", "offset": [27, 38]}, {"key": "for-clarity", "type": "clause", "offset": [45, 56]}, {"key": "types-of", "type": "clause", "offset": [143, 151]}, {"key": "composition-of-matter", "type": "definition", "offset": [169, 190]}, {"key": "process-patents", "type": "definition", "offset": [214, 229]}], "snippet": "means the countries listed on Schedule 1.49. For clarity, the list of Core Countries set forth on Schedule 1.49 may be different for different types of patents, such as composition of matter patents, manufacturing process patents, methods of treatment, etc.", "hash": "d5df8701566619c7c29e9eef4ee195b1", "id": 7}, {"samples": [{"hash": "dmHFEV6ZdV1", "uri": "https://www.hd.eneos.co.jp/english/ir/library/statement/jx/2013/pdf/jx_en_ts_fy2013.pdf", "label": "www.hd.eneos.co.jp", "score": 6.2610914069, "published": false}, {"hash": "6QG91cgCHoO", "uri": "https://www.hd.eneos.co.jp/english/ir/stock/meeting/pdf/jx_en_r_gmi_fy2014_01.pdf", "label": "www.hd.eneos.co.jp", "score": 4.2039698836, "published": false}], "size": 2, "snippet_links": [{"key": "business-is", "type": "definition", "offset": [29, 40]}, {"key": "the-future", "type": "clause", "offset": [75, 85]}, {"key": "the-business", "type": "clause", "offset": [109, 121]}], "snippet": "means countries in which our business is expected to continue to expand in the future by taking advantage of the business foundation currently held and the knowledge accumulated.", "hash": "78e8a54798458dfed18c955ec57a117b", "id": 8}, {"samples": [{"hash": "21jqhJHwbSo", "uri": "/contracts/21jqhJHwbSo#core-countries", "label": "Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)", "score": 27.9952087611, "published": true}, {"hash": "bWfZFtNszMb", "uri": "/contracts/bWfZFtNszMb#core-countries", "label": "Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)", "score": 27.7789185489, "published": true}], "size": 2, "snippet_links": [], "snippet": "has the meaning set forth in Schedule 7.3.1(c)", "hash": "a92f5bf1cc187aa6056994f0279bddec", "id": 9}, {"samples": [{"hash": "bA4m7e8HD3o", "uri": "/contracts/bA4m7e8HD3o#core-countries", "label": "Research, License, Supply and Royalty Agreement (Ribozyme Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "3vlCbNH7VRI", "uri": "/contracts/3vlCbNH7VRI#core-countries", "label": "Research, License, Supply and Royalty Agreement (Ribozyme Pharmaceuticals Inc)", "score": 18.0, "published": true}], "size": 2, "snippet_links": [{"key": "the-united-states", "type": "definition", "offset": [6, 23]}, {"key": "members-of-the", "type": "clause", "offset": [41, 55]}, {"key": "european-patent-convention", "type": "definition", "offset": [56, 82]}, {"key": "european-patent-office", "type": "definition", "offset": [87, 109]}, {"key": "no-party", "type": "clause", "offset": [146, 154]}, {"key": "right-to-file", "type": "clause", "offset": [170, 183]}, {"key": "patent-application", "type": "clause", "offset": [188, 206]}, {"key": "relating-to", "type": "definition", "offset": [207, 218]}, {"key": "joint-invention", "type": "clause", "offset": [221, 236]}, {"key": "developed-technology", "type": "definition", "offset": [248, 268]}, {"key": "in-accordance-with", "type": "definition", "offset": [276, 294]}, {"key": "this-section-xiii", "type": "clause", "offset": [295, 312]}], "snippet": "means the United States, Canada, Europe (members of the European Patent Convention via European Patent Office applications), Japan and Australia. No Party shall have the right to file any patent application relating to a Joint Invention within the Developed Technology except in accordance with this Section XIII.", "hash": "1c05bc1c6b2a4ac79156188f9216d9ae", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIXY29yZS1jb3VudHJpZXMjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Core Countries", "size": 44, "snippet": "means [***] and [***] and \u201cCore Country\u201d means any one of them;", "id": "core-countries", "examples": ["In the event that either Party wishes to seek Patent protection with respect to any Joint Invention outside the <strong>Core Countries</strong>, it shall notify the other Party hereto.", "Subject to Sections 9.4.2, the Parties will share equally all expenses and fees associated with the filing, prosecution, issuance and maintenance of any Patent Application and resulting Patent for a Joint Invention in the <strong>Core Countries</strong> and other agreed countries or multinational jurisdictions.", "The parties will share equally all expenses and fees associated with the filing, prosecution, issuance and maintenance of any patent application and resulting patent for a Joint Invention in the <strong>Core Countries</strong> and other agreed countries.", "Subject to Section 12.4.3 below, it is understood that, after the termination of the RESEARCH PROGRAM, the parties shall share equally the expenses and fees associated with the filing, prosecution, issuance and maintenance of any patent application and resulting patent for a Joint Invention in the <strong>Core Countries</strong> and other agreed countries.", "The parties will share equally all expenses and fees associated with the filing, prosecution, issuance and maintenance of any patent application and resulting patent for a Joint Invention in the <strong>Core Countries</strong> and other agreed countries and such amounts shall be included within the Research Program funding described in Section 2.3.", "The parties will share equally all expenses and fees associated with the filing, prosecution, issuance and maintenance of any patent application and resulting patent for a Joint Invention in the <strong>Core Countries</strong> and other agreed countries and such amounts shall be included within the Research Program funding described in Section 2.3 of the Collaboration Agreement.", "Subject to Section 9.2.3(b) below, the parties will share equally all reasonable expenses and fees associated with the filing, prosecution, issuance and maintenance of any patent application and resulting patent for a Joint Invention in the <strong>Core Countries</strong> and other agreed countries in accordance with the agreed plan or a mutually agreed modification thereof.", "As used in this Agreement, &quot;<strong>Core Countries</strong>&quot; shall mean the United States, Canada, Europe (members of the European Patent Convention via European Patent Office applications), Japan and Australia.", "The parties will share equally all expenses and fees associated with the filing, prosecution, issuance and maintenance of any patent application and resulting patent for a Joint Technology in the <strong>Core Countries</strong> and other agreed countries and such amounts shall be included within the Research Program funding described in Section 2.3 of the Collaboration Agreement.", "Notwithstanding the license being granted for the Territory, it is hereby understood that Omthera (or its Affiliates or sub-licensees) undertakes Commercially Reasonable Efforts for the Commercial Launch of the Product(s) (post Regulatory Approval) in all <strong>Core Countries</strong> in a timely manner, [\u2026***\u2026]."], "related": [["major-market-countries", "Major Market Countries", "Major Market Countries"], ["participating-countries", "Participating Countries", "Participating Countries"], ["major-countries", "Major Countries", "Major Countries"], ["non-iom-country", "non-IOM country", "non-IOM country"], ["eligible-countries", "Eligible Countries", "Eligible Countries"]], "related_snippets": [], "updated": "2025-07-06T21:55:40+00:00"}, "json": true, "cursor": ""}}